Natco Pharma share rose after the company announced that Mylan Pharmaceuticals Inc & Novo Nordisk have reached a settlement of the US patent litigation related to generic Ozempic (Semaglutide)

Shares of Natco Pharma Ltd surged nearly 4.35 per cent to Rs 1,413.45 on Monday, commanding a total market capitalization close to Rs 25,000 crore.

The strong up move was seen in the stock price with the scrip touching the day's high of Rs 1,408.70 per share on the NSE, rising 4 percent.

With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their generic to Novo Nordisk's wildly popular type 2 diabetes drug Ozempic. | Mylan Pharmaceuticals and Novo Nordisk have reached a confidential settlement in a patent lawsuit tied to generic Ozempic,

Alongside the settlement, Novo and Viatris have asked the U.S. Patent and Trademark Office to terminate its review of the validity of the Danish drugmaker’s semaglutide patents.

Mylan Pharmaceuticals Inc and Novo Nordisk, the original patent holder for Ozempic, have reached a settlement in the US patent litigation concerning the drug, Natco Pharma informed the stock exchanges in a filing.

According to data from the BSE index, the stock has achieved multibagger gains over the last two years, climbing 122.04%.

Hyderabad: NATCO Pharma Limited has announced that its partner Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement of the U.S. patent litigation related to generic

Mylan and Novo Nordisk have reached a confidential settlement over the generic version of Ozempic, with Natco Pharma holding Sole First-to-File (FTF) status for multiple strengths of Ozempic and Wegovy.

According to a report by news agency PTI, NATCO and Mylan have partnered for the development of generic Ozempic (Semaglutide) products, the company said in a regulatory filing. Ozempic is a prescription medication patented by Novo Nordisk.